IDEAYAs Loss Widens as Revenue Beat Fails to Move the Stock

IDEAYA Biosciences (IDYA) reported fiscal 2026 Q2 earnings on August 4, 2026. The company delivered a revenue beat but missed on EPS, widening its net loss significantly compared to the prior year.

IDEAYA Biosciences reported a revenue beat for Q2 2026, generating $8.86 million against an expected $7.45 million. However, the company missed on earnings per share, posting a loss of $1.22 versus the estimated $1.06 loss. Guidance remains unchanged with a cash runway extending into 2030.

Revenue

The total revenue of IDEAYA Biosciences increased by 0.0% to $8.86 million in 2026 Q2, up from $0 in 2025 Q2.

Earnings/Net Income

IDEAYA Biosciences's losses deepened to $1.22 per share in 2026 Q2 from a loss of $0.88 per share in 2025 Q2 (38.6% wider loss). Meanwhile, the company's net loss widened to $-112.45 million in 2026 Q2, representing a 45.1% increase from the $-77.49 million loss recorded in 2025 Q2. The Company has sustained losses for 5 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The EPS performance was poor as the loss per share widened significantly beyond analyst expectations.

Price Action

The stock price of IDEAYA Biosciences has edged down 0.51% during the latest trading day, has edged down 0.14% during the most recent full trading week, and has dropped 4.09% month-to-date.

Post-Earnings Price Action Review

The short answer is that a “buy on IDYA revenue miss” strategy cannot be backtested because the most recent earnings release was actually a revenue beat, not a miss. In the latest report, IDYA’s revenue was $8.86 million versus an expected $7.45 million, while EPS missed by $0.14. The latest available price history for IDYA shows the most recent close was $36.11 on August 4, 2026. Consequently, there is no qualifying “revenue miss” event to test in the verified data. However, alternative strategies such as buying on an EPS miss, buying on a revenue beat, or buying on a broader earnings headline miss are testable given the specific metrics reported. Even if rerun, earnings-based biotech trading is largely headline-driven rather than fundamentals-driven. For a stock like IDYA, the market often prices the news quickly, with the subsequent 30 days dominated by pipeline catalysts, dilution risk, and positioning, meaning the earnings miss itself may not be the sole driver of returns. Investors may choose to backtest strategy #1 (EPS miss) or strategy #3 (headline miss) depending on their preference.

CEO Commentary

Yujiro S. Hata, President and Chief Executive Officer, characterized the quarter as a successful step toward delivering best-in-class precision therapies, highlighting positive topline results from the registrational OptimUM-02 trial and ongoing NDA submission activities. He emphasized the pipeline’s readiness for key 2026 updates, including IDE849 data in SCLC and progress in MTAP-deleted cancers via IDE892 combinations. Citing over $1.2 billion in cash following a June financing, Hata expressed confidence in IDEAYA’s position to advance its pipeline through multiple data updates, maintaining an optimistic tone regarding the company’s strategic momentum and financial resilience.

Guidance

IDEAYA is filing a New Drug Application for darovasertib under the Real-Time Oncology Review program, with completion expected in the second half of 2026. Updated clinical data from OptimUM-01 and OptimUM-09 trials will be presented at ESMO in October 2026. The company plans to initiate a Phase 1 combination trial for IDE892 and RG6505 in the second half of 2026 and expects to share initial clinical data for IDE849 globally in the same period, with a goal to initiate registrational trials by year-end 2026. IDEAYA will host an R&D Day in Q4 2026 and maintains cash runway guidance into 2030 based on its current operating plan.

Additional News

In related corporate developments, Andres Ruiz Briseno, the Chief Accounting Officer at IDEAYA Biosciences, executed a notable transaction on July 7, 2026. Briseno sold 9,550 shares of the company's stock at an average price of $40.01, resulting in a total transaction value of $382,095.50. This divestiture represented a 26.52% decrease in his direct holdings, leaving him with 26,466 shares valued at approximately $1,058,904.66. The trade was officially disclosed in a document filed with the Securities and Exchange Commission. Additionally, institutional interest in IDEAYA has shifted recently, with Invesco Ltd. significantly increasing its position by 91.9% during the fourth quarter, now holding 238,314 shares worth $8.239 million. Furthermore, XTX Topco Ltd. acquired a new stake in the company during the same quarter, valued at approximately $2.288 million. These activities reflect evolving insider and institutional sentiment surrounding the cancer drug maker ahead of its upcoming earnings announcements and pipeline updates.